Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | editorial

Multiple myeloma: the biology, the clinic, and the future

verfasst von: Priv. Doz. Dr. Niklas Zojer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

The landscape of myeloma therapy has been changing quickly over the last 15 years, and when looking at drugs currently in development in clinical trials we can expect further “revolutions” in the near future. Immunomodulatory substances are at present the favored “backbones” of myeloma therapy, with new drugs like the antimyeloma antibodies evaluated in combination with lenalidomide/dexamethasone or the new oral proteasome inhibitor ixazomib evaluated in combination with thalidomide/dexamethasone. Such “chemotherapy-free” triple combinations have the potential to evolve to standards of care in relapsed disease. Just recently, a favorable outcome was reported for patients receiving therapy with carfilzomib/lenalidomide/dexamethasone when compared with lenalidomide/dexamethasone alone (ASPIRE study) and also pomalidomide was evaluated in triple combinations (e.g., combined with bortezomib/dexamethasone), with high response rates reported in relapsed/refractory disease. …
Literatur
1.
Zurück zum Zitat Willenbacher W, Willenbacher E. To maintain or not to maintain: treatment forever in myeloma? Memo 2015;8. doi:10.1007/s12254-014-0185-1. Willenbacher W, Willenbacher E. To maintain or not to maintain: treatment forever in myeloma? Memo 2015;8. doi:10.1007/s12254-014-0185-1.
2.
Zurück zum Zitat Fillitz M, Seebacher A, Panny M. Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients. Memo 2015;8. doi:10.1007/s12254-015-0206-8. Fillitz M, Seebacher A, Panny M. Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients. Memo 2015;8. doi:10.1007/s12254-015-0206-8.
3.
Zurück zum Zitat Lechner D. Treatment of myeloma patients with renal impairment. Memo 2015;8. doi:10.1007/s12254-014-0193-1. Lechner D. Treatment of myeloma patients with renal impairment. Memo 2015;8. doi:10.1007/s12254-014-0193-1.
4.
Zurück zum Zitat Ludwig H, Hilbe W, Zojer N. New drugs on the horizon. Treatment of myeloma in 2020, a perspective. Memo 2015;8. doi:10.1007/s12254-014-0194-0. Ludwig H, Hilbe W, Zojer N. New drugs on the horizon. Treatment of myeloma in 2020, a perspective. Memo 2015;8. doi:10.1007/s12254-014-0194-0.
5.
Zurück zum Zitat Zojer N, Ludwig H. Tailoring treatment in myeloma: are there clues from biology? Memo 2015;8. doi:10.1007/s12254-015-0207-7. Zojer N, Ludwig H. Tailoring treatment in myeloma: are there clues from biology? Memo 2015;8. doi:10.1007/s12254-015-0207-7.
Metadaten
Titel
Multiple myeloma: the biology, the clinic, and the future
verfasst von
Priv. Doz. Dr. Niklas Zojer
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0199-3

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe